Zacks Investment Research·Jun 16, 2026
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCARNSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
InspireMD, Inc.(NSPR)Earnings, Financials & Key Ratios
NSPR•NASDAQ
$0.72
Price updated Jul 7, 2026
AboutInspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Show more
- Revenue$9M+28.1%
- EBITDA-$49M-46.4%
- Net Income-$49M-52.4%
- EPS (Diluted)-0.76
- Gross Margin29.5%+37.3%
- EBITDA Margin-541.66%-14.3%
- Operating Margin-546.97%-14.4%
- Net Margin-543.33%-19.0%
- ROE-106.88%-26.2%
NSPR Price & Volume
InspireMD, Inc. (NSPR) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Faces Severe Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Accelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary U.S. Regulatory Approval
Key Thesis Takeaways
- InspireMD is currently navigating a high-stakes transition as it attempts to leverage 122.2% year-over-year revenue growth to support its U.S.
- clinical trial ambitions.
- While international market adoption of the CGuard system appears to be gaining traction, the company's reliance on external financing and persistent operating losses remain significant headwinds.
- Investors should monitor the company's ability to achieve operational self-sufficiency before its cash reserves, which dropped to $11.4 million in 2026Q1, are fully exhausted.
Verdict Logic
the company's rapid depletion of cash reserves from $63.4 million in 2025Q3 to $11.4 million in 2026Q1 suggests a high probability of further dilutive financing to sustain operations.
NSPR Growth Metrics
InspireMD, Inc. (NSPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years14.54%
5 Years29.29%
3 Years20.19%
TTM54.38%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-3.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.34%
Return on Capital
10 Years-135.61%
5 Years-76.02%
3 Years-84.16%
Last Year-100.41%
NSPR Recent Earnings
InspireMD, Inc. (NSPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.16+15.8%
$0.19
Rev
$3M+25.8%
$3M
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.14+36.4%
$0.22
Rev
$3M+19.9%
$3M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.17+0.0%
$0.17
Rev
$3M-3.9%
$3M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.26-8.3%
$0.24
Rev
$2M+1.1%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.16vs $0.19+15.8% | $3Mvs $3M+25.8% |
| Q2 2026 | Mar 18, 2026 | $0.14vs $0.22+36.4% | $3Mvs $3M+19.9% |
| Q4 2025 | Nov 4, 2025 | $0.17vs $0.17+0.0% | $3Mvs $3M-3.9% |
| Q3 2025 | Aug 4, 2025 | $0.26vs $0.24-8.3% | $2Mvs $2M+1.1% |
Based on last 12 quarters of dataView full earnings history →
Latest NSPR News
Recent stock market news and headlines for InspireMD, Inc. (NSPR)
Peers Comparison
Key metrics vs top competitors for InspireMD, Inc. (NSPR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.72 | $33.62M | -0.94 | 28.11% | -543.33% | -106.88% | — | |
| $45.70 | $378.4M | 53.14 | 16.97% | 14.08% | 22.14% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $13.07 | $540.04M | -15.75 | -3.76% | -10% | -17.65% | — | |
| $140.85 | $9.06B | -68.71 | -89.41% | -648.27% | -17.76% | — | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — |
Compare NSPR vs Peers
InspireMD, Inc. (NSPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NSPR SEC Filings & Documents
InspireMD, Inc. (NSPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Jun 11, 2026·SEC
Material company update
May 22, 2026·SEC
Material company update
May 4, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when NSPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NSPR Frequently Asked Questions
InspireMD, Inc. (NSPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is InspireMD, Inc.'s revenue?
InspireMD, Inc. (NSPR) reported $10.8M in revenue for fiscal year 2025. This represents a 218% increase from $3.4M in 2009.
How fast is InspireMD, Inc. growing?
InspireMD, Inc. (NSPR) grew revenue by 28.1% over the past year. This is strong growth.
Is NSPR profitable?
InspireMD, Inc. (NSPR) reported a net loss of $37.3M for fiscal year 2025.
Dividend & Returns
What is NSPR's return on equity?
InspireMD, Inc. (NSPR) has a return on equity (ROE) of -106.9%. Negative ROE indicates the company is unprofitable.
What is InspireMD, Inc.'s free cash flow?
InspireMD, Inc. (NSPR) had negative free cash flow of $40.1M in fiscal year 2025, likely due to heavy capital investments.